Cefoxitin sodium: a clinical and pharmacological study

Publisher Website
Google Scholar
Abstract
In a clinical study, predominantly of patients with intra-abdominal sepsis, 14 (70%) of 20 patients were cured by cefoxitin sodium i.v. A further 6 (30%) patients improved. There were no clinical failures. Cefoxitin appears to possess the safety of the cephalosporins and penicillins, although a transient, slight disturbance of liver function was seen in 25% of the patients and phlebitis also occurred in 25%. No adverse effects on renal function were seen. In patients with normal renal function, cefoxitin is rapidly cleared from the blood. Administration of probenecid raises the blood levels of cefoxitin and prolongs their duration. Cefoxitin is likely to be a valuable agent in a variety of infections, particularly gut-associated sepsis. Dose schedules must now be defined, particularly for children and seriously ill patients.

This publication has 0 references indexed in Scilit: